AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
AAPL   321.27 (+0.75%)
MSFT   185.05 (+0.84%)
FB   238.76 (+1.63%)
GOOGL   1,440.13 (+1.90%)
AMZN   2,447.72 (+0.44%)
NVDA   362.80 (+0.48%)
CGC   20.64 (+5.47%)
BABA   205.92 (+3.11%)
TSLA   831.98 (+1.85%)
AMD   55.88 (+0.81%)
ACB   16.04 (+0.19%)
F   5.95 (+5.31%)
GILD   72.97 (-0.50%)
NFLX   417.91 (-2.66%)
BAC   23.78 (+4.90%)
BA   143.92 (+4.65%)
Log in

ASX:BOTBotanix Pharmaceuticals Stock Price, Forecast & News

A$0.04
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.04
Now: A$0.04
A$0.04
50-Day Range
A$0.02
MA: A$0.05
A$0.09
52-Week Range
A$0.02
Now: A$0.04
A$0.29
Volume1.63 million shs
Average Volume4.45 million shs
Market Capitalization$40.85 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. The company offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; and BTX 1701, a novel product for mild acne. Botanix Pharmaceuticals Limited is based in Perth, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-8-94820580

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.58 million
Cash FlowA$0.03 per share
Book ValueA$0.03 per share

Profitability

Miscellaneous

Employees10
Market Cap$40.85 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BOT News and Ratings via Email

Sign-up to receive the latest news and ratings for BOT and its competitors with MarketBeat's FREE daily newsletter.

Botanix Pharmaceuticals (ASX:BOT) Frequently Asked Questions

How has Botanix Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Botanix Pharmaceuticals' stock was trading at A$0.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BOT shares have decreased by 45.5% and is now trading at A$0.04. View which stocks have been most impacted by Coronavirus.

How were Botanix Pharmaceuticals' earnings last quarter?

Botanix Pharmaceuticals Ltd (ASX:BOT) issued its quarterly earnings data on Thursday, February, 28th. The company reported ($0.01) EPS for the quarter. View Botanix Pharmaceuticals' earnings history.

Has Botanix Pharmaceuticals been receiving favorable news coverage?

Headlines about BOT stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Botanix Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutBotanix Pharmaceuticals.

Who are some of Botanix Pharmaceuticals' key competitors?

What other stocks do shareholders of Botanix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Botanix Pharmaceuticals investors own include AgraFlora Organics International (AGFAF), Byron Energy (BYE), Harmony Gold Mining (HMY), Syrah Resources (SYR), Nike (NKE), Michael Hill International (MHJ), Lynas (LYC), Cobalt 27 Capital (KBLT), Eclipx Group (ECX) and BOD Australia (BDA).

Who are Botanix Pharmaceuticals' key executives?

Botanix Pharmaceuticals' management team includes the following people:
  • Mr. Matthew Callahan, Founder & Exec. Director (Age 46)
  • Dr. Michael Thurn Ph.D., COO & Exec. Director
  • Dr. Henry William Bosch, Chief Scientific Officer & Exec. Director
  • Dr. Stephane Levy, Chief Medical Officer
  • Mr. Simon Robertson B.Bus, M Appl. Fin, CA, Company Sec.

What is Botanix Pharmaceuticals' stock symbol?

Botanix Pharmaceuticals trades on the ASX under the ticker symbol "BOT."

What is Botanix Pharmaceuticals' stock price today?

One share of BOT stock can currently be purchased for approximately A$0.04.

How big of a company is Botanix Pharmaceuticals?

Botanix Pharmaceuticals has a market capitalization of $40.85 million and generates $7.58 million in revenue each year. Botanix Pharmaceuticals employs 10 workers across the globe.

What is Botanix Pharmaceuticals' official website?

The official website for Botanix Pharmaceuticals is www.botanixpharma.com.

How can I contact Botanix Pharmaceuticals?

Botanix Pharmaceuticals' mailing address is Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia. The company can be reached via phone at +61-8-94820580.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.